local semaglutide 'Don't Panic': expert on FDA weight loss drug deadline Mechanism of absorption of oral

2012 Sep 21;3:171

Hogan, et al (10)

And the long-term consequences

The FDA accepted it for filing on April 1, and by that announcement Repros had already dropped the brand, calling it its enclomiphene citrate product candidate, formerly known as Androxal. The indication it sought was narrower than anyone remembers, and the FDA wrote it out in full: NDA 207959, enclomiphene citrate 12.5 mg and 25 mg capsules, for the proposed treatment of secondary hypogonadism in fertile men (men with more than 15 million sperm/milliliter (ml)), younger than 60 years of age with a Body Mass Index (BMI) over 25 kilograms (kg)/meters squared (m2) (80 FR 50639)

And MOTS-C